Purpose The diagnosis of behavioural variant frontotemporal dementia (bvFTD) is challenging during the predementia stage when symptoms are subtle and confounding. Morphological and functional neuroimaging can be particularly helpful during this stage but few data are available. Methods We retrospectively selected 25 patients with lateonset probable bvFTD. Brain structural MRI and FDG PET were performed during the predementia stage (mean MMSE score 27.1 ± 2.5) on average 2 years before. The findings with the two imaging modalities were compared (SPM8) with those in a group of 20 healthy subjects. The bvFTD patients were divided into two subgroups: those with predominant disinhibition (bvFTD+) and those with apathy (bvFTD−). Results Hypometabolism exceeded grey matter (GM) density reduction in terms of both extension and statistical significance in all comparisons. In the whole bvFTD group, hypometabolism involved the bilateral medial, inferior and superior lateral frontal cortex, anterior cingulate, left temporal and right parietal cortices and the caudate nuclei. GM density reduction was limited to the right frontal cortex and the left medial temporal lobe. In bvFTD+ patients hypometabolism was found in the bilateral medial and basal frontal cortex, while GM reduction involved the left anterior cingulate and left inferior frontal cortices, and the right insula. In bvFTD− patients, atrophy and mainly hypometabolism involved the lateral frontal cortex and the inferior parietal lobule. Conclusion These findings suggest that hypometabolism is more extensive than, and thus probably precedes, atrophy in predementia late-onset bvFTD, underscoring different topographic involvement in disinhibited and apathetic presentations. If confirmed in a larger series, these results should prompt biomarker operationalization in bvFTD, especially for patient selection in therapeutic clinical trials.
Introduction
The most frequent subtype of frontotemporal dementia (FTD) is the behavioural variant (bvFTD), that is characterized by progressive deterioration in personality, social behaviour and cognition. Although genetic causes are increasingly recognized [1] , the majority of cases are still sporadic [2] . Diagnostic criteria include 'possible' FTD when at least three of six behavioural or cognitive hallmarks are found without significant impact on functional autonomy [3] . This stage would theoretically correspond to the mild cognitive impairment (MCI) construct of Alzheimer's disease (AD) [4] and often behavioural symptoms dominate in cognitive impairment, 'early apathy' and 'early disinhibition' being largely the most frequent presentations [3, 5, 6] . To delineate this stage, the concept of mild behavioural impairment has been proposed [7] . Interestingly, changes in morphological and/or functional neuroimaging are included in the criteria for probable FTD but not in those for possible FTD [3] . Yet neuroimaging changes would be even more relevant during the predementia stage, as in AD where neuroimaging biomarkers increase the likelihood of diagnosis during the MCI stage [8] . It has been shown that both atrophy [9, 10] and hypometabolism/hypoperfusion [6, [11] [12] [13] [14] [15] [16] [17] are detectable early in anterior cortical regions in overt FTD, when they can support the diagnosis [18] and help differentiate bvFTD from psychiatric disorders in the elderly [19] . In principle, hypometabolism/hypoperfusion, that are exquisitely sensitive to synaptic dysfunction [20] , should be detectable earlier and be more extensive than atrophy [15, 16, 21] The aim of this study was to verify whether hypometabolism is more extensive than, and thus probably precedes, atrophy in patients with probable bvFTD investigated during the predementia stage.
Methods Patients
Outpatients examined during the period 2011 -2013 were selected retrospectively from the clinical database of the Dementia Center of the University Hospital, with the following characteristics: (1) evaluated for the first time and with a diagnosis of possible bvFTD, thus without dementia [3] , (2) underwent both MRI, including volumetric T1-weighted sequences, and 18 F-FDG PET at baseline during the first diagnostic work-up, and (3) clinically followed until they developed probable bvFTD [3] . These constraints resulted in the selection of a group of patients with probable bvFTD investigated during the predementia stage. Specifically the predementia state was defined (1) according to the clinical diagnostic criteria for 'possible' FTD thus involving at least three of six behavioural or cognitive hallmarks but without a significant impact on functional autonomy, (2) by a score of 0.5 on the standardized Clinical Dementia Rating (CDR) administered according to the standard method [22] , and (3) by the lack of a substantial impact of disturbances on everyday living and autonomy (thus matching the concept of MCI) shown by both an unstructured clinical interview with informants and administration of the structured Activities of Daily Living (ADL) and Instrumental ADL (IADL) scales. The main exclusion criteria were a psychiatric diagnosis according to the DSM-IVr criteria, any somatic, metabolic or other neurological disease potentially accounting for the cognitive or behavioural disturbances. On MRI, brain infarcts and severe white matter disease (i.e. a score of 3 in any region on the AgeRelated White Matter Changes scale [23] ) were also exclusion criteria.
These criteria identified 25 patients for inclusion. None of the patients had signs or symptoms of motor neuron disease. The family history was positive for dementia or major psychiatric illnesses in at least one first-degree relative in ten and two patients, respectively. Genetic status with respect to C9orf72, TARDBP and PGRN mutations was available in all patients, and was negative. At the first evaluation, all patients underwent a battery of neuropsychological tests evaluating verbal learning and delayed recall, working memory, attention, cognitive flexibility, language, abstraction, and visuospatial abilities. Each patient's behavioural profile was assessed by means of the Neuropsychiatric Inventory (NPI). The neuropsychological test scores were corrected for age and education according to published normative data in the local language. The main demographic and clinical characteristics of the patients are presented in Table 1 and the mean neuropsychological test scores in Table 2 .
Patients were then divided into two subgroups according to the prevalence of positive or negative symptoms, established on the basis of clinical examination and unstructured interviews with the patients and their caregivers (Table 3) . Then the total NPI score and item subscores were compared between the two subgroups (t test) and significant differences were found for agitation, euphoria, disinhibition, irritability (significantly higher in the subgroup with positive symptoms, bvFTD+), depression and apathy (significantly more severe in the group with negative symptoms, bvFTD−; Table 4) .
Patients underwent clinical and neuropsychological follow-up until they developed signs and symptoms matching the diagnostic criteria for probable FTD, which occurred 6 to 43 months later (mean 22.7 ± 12.2 months) with a mean MMSE score of 23.5 ± 6.6. Dementia was established by clinical interviews with patients and caregivers using the structured CDR scale as well as the ADL and IADL questionnaires According to the current diagnostic criteria [3] , significant atrophy and/or hypometabolism in frontotemporal regions is needed to formulate the diagnosis of probable FTD. MRI and FDG PET images were qualitatively evaluated by a neurologist with expertise in neuroimaging (F.N.) and by a nuclear medicine physician with expertise in nuclear neurology (S.M.), respectively. Significant atrophy was detected in 15 patients (60 %), whereas significant hypometabolism was found in all patients.
Control subjects
Control subjects were healthy volunteers who gave their informed consent and had participated in a previous study [24] . Their healthy status was carefully checked by means of general medical history and clinical examination. Control subjects were submitted to the same exclusion criteria as the patients and underwent both MRI with T1-weighted volumetric sequences and FDG PET. Only subjects with a CDR score of 0 and a normal MMSE score (i.e. >26) were included. Control subjects underwent the same neuropsychological test battery as the patients, and only subjects with normal scores (Z score >−1.5) in all tests were further considered. The healthy status of all 20 subjects was confirmed by clinical interview 1 year later. Demographic and neuropsychological characteristics are presented in Tables 1 and 2 , respectively. The study protocol was approved by the local Ethics Committee and an informed consent was signed by all participants, in compliance with the Declaration of Helsinki.
18
F-FDG PET protocol and preprocessing FDG PET was performed according to the guidelines of the European Association of Nuclear Medicine [25] . Briefly, subjects fasted for at least 6 h. Before radiopharmaceutical injection, blood glucose was checked and was <7.8 mmol/l in all subjects. After 10 min rest in a quiet and darkened room, with their eyes closed and no ear plugs, subjects were injected with approximately 200 MBq of 18 F-FDG via a venous cannula. They remained in the room for 30 min after the injection and then moved to the PET room where scanning was started approximately 45 min after the injection. A polycarbonate head holder was used to reduce head movement during the scan. Images were acquired using a Siemens Biograph 16 PET/CT system with a total axial field of view of 15 cm and no interplane gap. The scan acquisition time was 15 min in three-dimensional mode. Images were reconstructed using an ordered subsets expectation maximization algorithm (16 subsets and six iterations) with a reconstructed voxel size of 1.33 × 1.33 × 2.00 mm. Attenuation correction was based on the CT scan. DICOM files were exported and converted into Analyse files.
FDG PET images were subjected to affine and nonlinear spatial normalization into the Talairach and Tournoux space using SPM8 (Wellcome Department of Cognitive Neurology, London, UK) implemented in MATLAB 7.5 (MathWorks, Natick, MA). The spatially normalized set of images was then smoothed with a 10-mm isotropic gaussian filter to blur individual variations in gyral anatomy and to increase the signalto-noise ratio. All the default choices of SPM8 were followed with one exception. Since it has been shown that the use of the tracer unmatched PET template to normalize brain scans may generate inconsistent results [24] and because the default SPM brain PET template is an H 2 15 O template, a customized brain FDG PET template was used [24] . Age (years), mean ± SD 71.9 ± 7.8 71.6 ± 5. 
MRI protocol and preprocessing
MRI volumes were obtained using a 1.5-T scanner (Signa Excite; GE Healthcare, Milwaukee, WI) with an eight-coil transmit-receive head coil acquiring volumetric T1 imaging using a coronal T1-weighted 3D spoiled gradient recalled (SPGR) sequence (TR/TE 10.0 ms/4.5 ms, flip angle 8°, field of view 24 × 24 cm, matrix 256 × 256). MRI images were obtained within 2 months of the PET examination. Images were preprocessed with SPM, using a modified optimized voxel-based morphometric technique [26] . First, a customized sample-specific whole-brain template was computed, and an a priori map for grey matter (GM), white matter and cerebrospinal fluid were determined by segmenting the sample-specific whole-brain template into the three components based on image intensity classification and probability of tissue class membership. Each individual MR scan was normalized to the wholebrain sample-specific template and then segmented into GM, white matter and cerebrospinal fluid components using information from the sample-specific tissue classification templates. The individual GM images were further spatially normalized to the sample-specific GM using a 12-parameter affine transformation and nonlinear adjustments with 7 × 8 × 7 basis functions. The segmented, normalized images were finally smoothed with an 8-mm full-width at half-maximum gaussian kernel to compensate for interindividual variability and conform the data to a gaussian distribution to enable the use of the random field theory which provides corrected statistical inference.
Statistics
FDG PET and segmented GM maps were compared between the control group and the whole group of bvFTD patients. Then, to fully explore GM density reduction and hypometabolic patterns related to different behavioural profiles, FDG PET and GM images from the bvFTD+ and bvFTD− subgroups were independently compared with those from the control group. All comparisons were performed on a voxel-by-voxel basis using the SPM8 two-sample t-test option, with age and education as nuisance variables. All SPM T maps were displayed using an uncorrected p < 0.001 at peak level. Clusters of differences were regarded as significant if they survived at a threshold of p < 0.05, corrected for familywise error at the cluster level. Only significant clusters containing at least 100 (FDG PET) or 50 (GM density) voxels were taken into consideration. The p < 0.001 height threshold at the voxel level was adopted to avoid type II errors attributable to over-conservative thresholds [27] . In fact, given the exploratory nature of the study and especially considering the relatively low sensitivity of PET and MRI without repeated measures, higher thresholds could have led to falsenegative results. The SPM coordinates were corrected to match the Talairach coordinates using BrainMap GingerALE 2.3 [28] . Brodmann areas (BA) were then identified at a range of 0 to 3 mm from the corrected Talairach coordinates of the SPM output isocentres, after importing the corrected coordinates by means of Talairach Client (http://www.talairach.org/index.html). 
Results
Comparisons between the control and bvFTD group
The bvFTD group showed lower GM density in the right inferior frontal gyrus (BA9-44) as well as in the thalamus, claustrum and parahippocampal gyrus in the left hemisphere (Fig. 1a , Table 5 ). Hypometabolism was found in a larger cluster in both hemispheres involving the superior (bilateral BA10 and right BA9), medial (BA10) and inferior (right BA13, left BA45) frontal gyri, the anterior cingulate gyrus (bilateral BA32 and right BA24) and the caudate nucleus, and in the left hemisphere involving the middle frontal gyrus (BA46) and the superior temporal gyrus (BA22). A smaller cluster was present in the right inferior parietal lobule (BA40; Fig. 1b , Table 6 ).
Comparisons between the control group and bvFTD+ subgroup
In the bvFTD+ subgroup a reduction in GM density was found in two small clusters involving the inferior frontal gyrus (BA9-44) and cingulate gyrus (BA31) in the left hemisphere, and the insula and claustrum in the right hemisphere (Fig. 2a , Table 5 ). However, hypometabolism was highlighted in two larger clusters involving the medial frontal gyrus (bilateral BA25 and right BA10) in both hemispheres, the inferior frontal gyrus (BA45), postcentral gyrus (BA40-43) and caudate nucleus in the left hemisphere, and the superior temporal gyrus (BA38) and insula in the right hemisphere (Fig. 2b , Table 6 ).
Comparisons between the control group and bvFTD− subgroup
In the bvFTD− subgroup GM density reduction was found in the left superior (BA10) and right inferior (BA9) frontal gyri, and the left precentral gyrus (BA44) and left inferior parietal lobule (BA40; Fig. 2c , Table 5 ). In contrast, two clusters of significant hypometabolism were found including the left superior (BA10) and inferior (BA47) frontal gyri, the bilateral inferior parietal lobule (BA40) and the right precentral gyrus (BA44) (Fig. 2d , Table 6 ).
Discussion
In this multi-modal imaging study we demonstrated significant GM atrophy and hypometabolism in a group of patients with late-onset bvFTD in the predementia stage. In particular, cortical and subcortical hypometabolism was significantly more extensive than GM atrophy, suggesting that functional network damage occurs earlier than anatomical damage. Disinhibited or apathetic presentations were shown to be associated with different functional patterns even in the early stage of bvFTD. This retrospective study was indeed designed Fig. 1 Comparison between healthy controls and the whole group of bvFTD patients in the predementia stage. Clusters with significant grey matter density reduction are shown superimposed on a MRI template (a) while clusters with significant glucose hypometabolism are superimposed on a PET template (b). In the whole group grey matter density reduction involves the right inferior frontal gyrus, thalamus, claustrum and parahippocampal gyrus in the left hemisphere (a) while hypometabolism is seen in the frontal lobes, anterior temporal lobes, caudate nuclei and thalami of both hemispheres (b). The colour bars indicate the level of Z scores for significant voxels. Note that the range of colour bars is 0 -4 for MRI and 0 -6 for FDG PET reflecting the higher level of statistical significance for the latter. See Tables 5 and 6 for details of Talairach coordinates to analyse data from patients matching the highest level of certainty for the diagnosis of bvFTD in vivo, but studied on average about 2 years before the diagnosis of dementia, when they were evaluated for the first time. As in AD, attempts to characterize the prodromal stage of bvFTD are ongoing and may help the planning of interventions and the interception of early disease for clinical trials [16] .
Hypometabolism and GM density reduction in predementia bvFTD patients
The finding that cortical and subcortical hypometabolism is more extensive than, and thus probably precedes, GM atrophy is in keeping with a recent study reporting insula, orbitofrontal and anterior cingulate hypometabolism without atrophy in 9 progranulin mutation carriers and 11 noncarriers without dementia [16] . Of note, a study evaluating FDG PET only in patients eventually developing bvFTD but without signs of atrophy showed a specificity of 92 % and a sensitivity of 47 % for FDG PET [7] . In another study a substantial overlap between hypometabolism and GM density reduction comparing MAPT gene carriers and noncarriers was found, but comparisons with healthy controls were not carried out [29] . In 14 patients with mild but overt FTD, including all FTD subtypes, atrophy and hypometabolism showed a greater overlap than in subjects with subjective cognitive impairment [15] , but again FDG PET was more accurate than structural MRI in differentiating these 14 patients from controls [30] . Also, in FTD-amyotrophic lateral sclerosis complex a considerable overlap between atrophy and hypometabolism was found but hypometabolism exceeded atrophy in several regions [31] . These data suggest that changes seen on FDG PET appear earlier than those seen on structural MRI at the very beginning of the disease, whilst there is more overlap between the findings of the two imaging modalities during the overt dementia stage. This is in accordance with the editorial opinion of Rabinovici and Boeve [32] commenting on the results of Chiu et al. [14] . In contrast, a negative FDG PET scan in a patient with suspected early FTD (i.e. possible FTD) should identify benign phenocopies that eventually do not convert to overt FTD, as also suggested by other authors [15, 19, 33] . In our bvFTD group hypometabolism involved not only the frontotemporal regions and insula, but also the caudate Uncorrected p < 0.001 at peak level and p < 0.05, corrected for multiple comparisons with the family-wise error option, at cluster level were accepted as statistically significant Uncorrected p < 0.001 at peak level and p < 0.05, corrected for multiple comparisons with the family-wise error option, at cluster level were accepted as statistically significant nuclei and distant brain regions, functionally connected with the frontal cortex via the frontoparietal bundles, such as the inferior parietal lobule. The caudate nucleus is a key part of the frontostriatal network and contributes to executive dysfunction in FTD, while the finding of parietal hypometabolism highlights the specific mechanism underlying reduced glucose uptake, that is, synaptic disconnection from distant (frontal) regions. Instead, GM atrophy was confined to smaller clusters in the bilateral medial frontal gyrus, left thalamus and medial temporal lobe structures. These findings confirm that FDG PET is more sensitive than MRI morphometry in detecting cortical damage in the early stages of bvFTD, since changes specifically targeting synaptic dysfunction and rarefaction [20] precede atrophy at the same sites as reported for other neurodegenerative diseases [34] . The relatively low sensitivity of structural MRI has already been shown in a study in 51 bvFTD patients, about half of whom failed to show significant atrophy by visual analysis even 5 years on average after diagnosis [35] . We also found some areas of overlapping atrophy and hypometabolism, and some small areas of atrophy without h y p o m e t a b o l i s m . A t r o p h y w i t h o u t s i g n i f i c a n t Fig. 2 Comparison between healthy controls and the bvFTD+ subgroup (a, b), and the bvFTD− subgroup (c, d). Clusters with a significant reduction in grey matter density are shown superimposed on a MRI template (a, c) while clusters with significant glucose hypometabolism are superimposed on a PET template (b, d). In the bvFTD+ subgroup, the grey matter density reduction can be seen in the left inferior frontal gyrus and cingulate gyrus, and in the right insula and claustrum (a), and hypometabolism is in the bilateral medial frontal gyri, left inferior frontal gyrus, postcentral gyrus and caudate nucleus, as well as in the right superior temporal gyrus and insula (b). In the bvFTD− subgroup (c, d), the grey matter density reduction is in the left superior and right inferior frontal gyri, left precentral gyrus and left inferior parietal lobule (c), and hypometabolism is in the left superior and inferior frontal gyri, bilateral inferior parietal lobule and right precentral gyrus (d). The colour bars indicate the level of Z scores for significant voxels. Note that the range of colour bars is 0 -4 for MRI and 0 -6 for FDG PET reflecting the higher level of statistical significance for the latter. See Tables 5 and 6 for details of Talairach coordinates hypometabolism was found in the left hippocampus, parahippocampal gyrus and thalamus, thus reproducing a similar finding in AD [30] that has been explained by either the relatively lower accuracy (i.e. spatial resolution) of FDG PET as compared with MRI in deep, small structures near the median line or hypothesizing a metabolic compensation mechanism at those sites [36] .
The present group of bvFTD patients was characterized by a rather late age at onset (mean 71.7 years), the same as that reported in a recent cohort of patients with late-onset bvFTD [37] . In a recent, large study with an upward cut-off of 75 years, the patients' mean age was 62.7 years, thus not so far from ours if that cut-off had not been used [19] . Indeed, bvFTD patients older than 65 years are increasingly recognized [38] . Thus our group can be characterized as having 'late-onset' bvFTD and the results should not be generalized to include those with 'early-onset' bvFTD. The relatively old age of the patients at onset could have been a result of the nature of our centre that is a neurological unit devoted to dementia of the elderly and of the peculiarities of our geographic area with a rather high prevalence of elderly people. A similar phenomenon has been found in patients with de novo Parkinson's disease, who show a rather late mean age at onset of 68 years [39] .
Networks underlying different behavioural presentations
As has been shown in patients with overt bvFTD, integration of behavioural and imaging assessments confirmed that the disinhibited or apathetic presentations are associated with different sites of both functional [6, 13] and structural [40] damage. Both hypometabolism and atrophy were more evident in orbitofrontal and temporal brain structures in disinhibited patients and in the dorsolateral frontal cortex in apathetic patients. Previous studies have shown that a major variable determining the behavioural manifestations of FTD at onset is the initial location of the disease [6, 11, 12] . It has been suggested that apathy is associated with more widespread cortical atrophy, mainly involving the dorsolateral frontal cortex [5] . Our results support this concept for at least two reasons, strictly related to our multimodal imaging approach. First, GM density reduction was indeed more extensive in the bvFTD− than in the bvFTD+ subgroup. Second, in the bvFTD− subgroup, clusters of atrophy and metabolic impairment in the dorsolateral frontal cortex tended to overlap to a greater extent than in the bvFTD+ subgroup, suggesting that more extended atrophy was already present together with hypometabolism at the first evaluation.
By contrast, in the bvFTD+ subgroup, clusters of hypometabolism were much more extensive than GM density reduction involving the inferomedial frontal cortex, caudate nucleus and superior temporal cortex. Accordingly, these patients might be at an earlier stage of the disease because their disinhibited and aggressive behaviour has a higher negative social impact, and thus they might present for neurological consultation even earlier than bvFTD− patients. Indeed, both the NPI and the MMSE scores tended to be higher in the bvFTD+ subgroup, although not significantly, indicating a more severe behavioural impact but with milder cognitive impairment. The bvFTD+ subgroup, characterized by hypometabolism extending to the temporal lobes, showed significantly higher NPI scores for the agitation, irritability and euphoria items. It has been previously suggested that dysthymia and agitation are particularly associated with right temporal function [13] that affects, anger, sadness and fear, and may be responsible for exaggerated reactions to sensory stimuli [41] .
Involvement of the striatum in the bvFTD group with socially inappropriate behaviours may be expected as the striatum plays a key role in the system responsible for reinforcement and reward, as well as for goal-directed behaviours [42] . Similarly lack of significant involvement of the basal ganglia in the apathetic subgroup is in keeping with the hypothesis that the aetiology of apathy seen in bvFTD patients differs from that in patients with damage to the basal ganglia possibly reflecting the direct involvement of the prefrontal cortex that may contribute to loss of motivation [43] . Finally, the more prominent structural and functional damage in the insula in the bvFTD+ subgroup might reflect its role in self-awareness and emotions. The insula is involved in decision-making processes by integrating information about the internal emotional/ arousal states and the risk or uncertainty associated with current decisions [44] .
The main strengths of this study are the availability of both morphological and functional data in the same patients, both collected during the predementia stage of bvFTD. The main limitations are the limited number of patients in each bvFTD subgroup, the availability of only the most frequent genetic markers, and the lack of histopathological confirmation. Another potential limitation is that we did not use the FTLD −modified CDR [45] to generate a 'global' rating, although a retrospective evaluation of the added 'language' domain led to a score of 0 or 0.5, while the other domain 'behaviour' could not be retrospectively evaluated. This choice might have influenced patient selection to some extent.
In conclusion, both hypometabolism and GM density reduction can be found in the predementia stage of bvFTD, with some overlap. However, hypometabolism is far more extensive and with more highly significant differences than GM atrophy as compared with controls. Combined structural and functional analysis of behavioural profiles allowed early frontolimbic and frontoparietal functional network damage to be identified in bvFTD patients. The findings related to patients' behavioural profiles confirm that the disinhibited and apathetic presentations are mainly associated with different functional patterns. These findings support the use of neuroimaging, especially FDG PET, to reveal functional failure in predementia bvFTD patients to support the clinical diagnosis during this early stage. This may have implications for therapeutic clinical trials to exclude patients with more benign phenocopies. Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The study protocol was approved by the local Ethics Committee.
Informed consent Informed consent was obtained from all individual participants included in the study.
